Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

78.59USD
9:00pm BST
Change (% chg)

$-2.67 (-3.29%)
Prev Close
$81.26
Open
$80.95
Day's High
$81.68
Day's Low
$78.29
Volume
272,641
Avg. Vol
295,666
52-wk High
$153.80
52-wk Low
$78.29

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 85.83 33.69
EPS (TTM): -5.12 -- --
ROI: -33.58 0.58 14.30
ROE: -39.86 1.62 16.03

Early approval of Alnylam's gene-silencing drug in question

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

27 Sep 2018

UPDATE 4-Early approval of Alnylam's gene-silencing drug in question

* Co still plans to discuss potential early approval with FDA

27 Sep 2018

UPDATE 1-Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

10 Aug 2018

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

10 Aug 2018

Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

10 Aug 2018

BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics

* ALNYLAM REPORTS PRECLINICAL DATA DEMONSTRATING CENTRAL NERVOUS SYSTEM (CNS) DELIVERY OF RNAI THERAPEUTICS

08 May 2018

BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

03 May 2018

BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran

* ALNYLAM ACHIEVES ALIGNMENT WITH FDA ON ACCELERATED DEVELOPMENT PATH FOR LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)

03 May 2018

BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran

* ALNYLAM REPORTS NEW CLINICAL RESULTS FROM THE APOLLO PHASE 3 STUDY OF PATISIRAN AT THE AMERICAN ACADEMY OF NEUROLOGY 2018 ANNUAL MEETING

24 Apr 2018

BRIEF-Alnylam Receives Positive Opinion For Orphan Drug Designation In EU For ALN-TTRsc02, For Treatment Of Transthyretin-Mediated Amyloidosis

* ALNYLAM RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ALN-TTRSC02, A SUBCUTANEOUSLY DELIVERED INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN-MEDIATED AMYLOIDOSIS Source text for Eikon: Further company coverage:

23 Apr 2018

Earnings vs. Estimates